Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Prior treatment

• Patients with evidence of abdominal free air not explained by paracentesis or recent surgical procedure (prior, current or planned treatment).
• Prior treatment of any adoptive T cell therapy.
• Current or recent treatment (within the 14-day period prior to Day 0) with any immune suppressive drug
• Minor surgical procedures within 2 days prior to Day 0 (including central venous access device placement for chemotherapy administration, tumor biopsies, needle aspirations).

Other illness

• Patients with ovarian tumors with low malignant potential (i.e. borderline tumors);
• Serious active infection requiring i.v. antibiotics
• Subject infected with HCV (HCV antibody positive), or HIV (HIV antibody positive),Treponema pallidum antibody positive or TB culture positive.

Lab values

• Inadequate bone marrow function with
  • absolute neutrophil count \< 1,000/mm\^3;
  • platelet count \< 100,000/mm\^3;
  • Hb \< 9 g/dL.
• Inadequate liver and renal function with
  • serum (total) bilirubin \> 1.5 x ULN;
  • AST \& ALT \> 2.5 x ULN (\> 5 x ULN in patients with liver metastases);
  • alkaline phosphatase \> 2.5 x ULN;
  • serum creatinine \>2.0 mg/dl (\> 177 μmol/L);
  • urine dipstick for protein uria should be \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo 24 hour urine collection and must demonstrate \< 1 g of protein/24 hr.

Other

• Pregnant or lactating females.

• Written, informed consent obtained prior to any study-specific procedures.
• Age older than 10 years.
• Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1.
• Expected survival ≥ 12 weeks.
• Histologically confirmed and documented high risk International Federation of Gynecology and Obstetrics (FIGO): Stage II-IV.
• Not pregnant, and on appropriate birth control of childbearing potential.
• Initial hematopoietic reconstitution with
  • neutrophils (ANC) ≥ 1,000/mm\^3;
  • platelet (PLT) ≥ 100,000/mm\^3.
• Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with
  • serum creatinine ≤ 2×ULN;
  • serum bilirubin ≤ 2×ULN;
  • AST/ALT ≤ 2×ULN;
  • ALKP ≤ 5×ULN;
  • serum bilirubin. 2.0 is acceptable in the setting of known Gilbert's syndrome.
• Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) test negative.